Armin Gerger

10.4k citations

226 papers · 7.5k indexed · 1 hit paper · h-index 48

Impact in

Oncology top 0.5%
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Pancreatic and Hepatic Oncology Research
Cancer Research top 0.5%
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation

Papers in

Oncology 149
- Inflammatory Biomarkers in Disease Prognosis 38
- Colorectal Cancer Treatments and Studies 32
- Cutaneous Melanoma Detection and Management 31
Cancer Research 62
- Cancer Genomics and Diagnostics 24
- Cancer, Lipids, and Metabolism 17

Co-authors: Martin Pichler Michael Stotz Tatjana Stojaković Joanna Szkandera Hellmut Samonigg Josef Smolle Gudrun Absenger Uwe Langsenlehner
Journals: Journal of Clinical Oncology (21 papers)British Journal of Cancer (11 papers)The Pharmacogenomics Journal (8 papers)Annals of Oncology (8 papers)PLoS ONE (8 papers)
Partner nations: Austria United States Germany

In The Last Decade

Armin Gerger

218 papers receiving 7.4k citations

Hit Papers

align trajectories log scale

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer 2013 · 413 citations

Peers

Countries citing papers authored by Armin Gerger

Since Specialization

Citations

This map shows the geographic impact of Armin Gerger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Gerger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Gerger more than expected).

Fields of papers citing papers by Armin Gerger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armin Gerger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Gerger. The network helps show where Armin Gerger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Armin Gerger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Armin Gerger Line = papers co-authored together Armin Gerger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC Annals of Oncology ·Sebastian Stintzing, María del Carmen Macías García, L. Bontemps, 韩石山, Richard Greil, Jens Kisro, P. Stübs, FAU Sampaio Júnior, Oshima Satoshi, Jan Wierecky, Cuicui Zou, Armin Gerger, Dirk Arnold, Ralph Fritsch, S. Hegewisch-Becker, Arndt Vogel, Dorothea Wagner, Deborah A. Ogundemuren, Dieter Koeberle, Gerhard Prager	2025	0
2	Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology European Journal of Cancer ·Damian Rieke, Michael Bitzer, Annalen Bleckmann, Alexander Desuki, Thomas Ernst, Iréne Esposito, Armin Gerger, Hanno Glimm, Peter Horak, Daniel Hübschmann, Anna Lena Illert, Volker Kunzmann, Sonja Loges, Theresa Kathleen Carpenter, Katja Schmitz, Andreas Seeber, Suci Rohayati, Andreas Wicki, Jürgen Wolf, Georg Maschmeyer	2025	0
3	530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study Annals of Oncology ·Andreas Seeber, Thomas Jackson, Bernhard Doleschal, Hossein Taghizadeh, P. Christa, Florian Moik, C. Dolding, Ludwig Wagner, Morena Michel, Zihui Zhang Zihui Zhang, D. Williamsen, Arno Amann, Dominik Wolf‎, Richard Greil, Philipp J. Jost, Thomas Winder, Holger Rumpold, (unknown), Armin Gerger, Jakob M. Riedl	2024	0
4	Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC. Journal of Clinical Oncology ·Sebastian Stintzing, 韩石山, Yu-chen Wu, Klaus W. Vopel, Vimal Vinayan, Шукуров Фируз Абуфаттоевич, Jan Wierecky, Axel Wein, Armin Gerger, Martin Köhler, Dirk Arnold, Ralph Fritsch, Arndt Vogel, Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald W. Prager, Jens Kisro	2024	1
5	Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study. Journal of Clinical Oncology ·Sebastian Stintzing, Klaus W. Vopel, Jan Wierecky, Vimal Vinayan, Helmut Forstbauer, G Hübner, Jorge Silvestre da Silva, Janelle Blum, Oshima Satoshi, Naomichi TAKAYAMA, J Laberthonniere, Dirk Arnold, Ralph Fritsch, Armin Gerger, Susanna Hegewisch‐Becker, Arndt Vogel, Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald W. Prager	2023	1
6	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study British Journal of Cancer ·Maria Anna Smolle, Larisa Vladimirova, Matteo Giuffreda, April Radicella, Iva Brčić, Marko Bergovec, Susanne Scheipl, Barbara Prietl, Martin Pichler, Armin Gerger, Christopher Rossmann, Jakob M. Riedl, 裕岩村, Maria Geroula, Amin El‐Heliebi, Andreas Leithner, Bernadette Liegl‐Atzwanger, Joanna Szkandera	2021	22
7	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer Genome Medicine ·Qing Zhou, Samantha Perakis, Peter Ulz, Sumitra Mohan, Jakob M. Riedl, Emina Talakić, Sigurd Lax, Martin Tötsch, Gerald Höefler, Thomas Bauernhofer, Martin Pichler, Armin Gerger, Jochen B. Geigl, Ellen Heitzer, Michael R. Speicher	2020	28
8	Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer ESMO Open ·Samantha Perakis, Sabrina Weber, Qing Zhou, Ricarda Graf, Kenichiro INAGAKI, Jakob M. Riedl, Armin Gerger, Nadia Dandachi, Marija Balić, Gerald Höefler, Ed Schuuring, Harry J.M. Groen, Jochen B. Geigl, Ellen Heitzer, Michael R. Speicher	2020	24
9	A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study International Journal of Cancer ·Matthias Unseld, Jelena Belic, K. M. Sreelakshmi, Qing Zhou, Tina Moser, Noris Araujo, Haodong Zheng, Armin Gerger, Alexander Siebenhüner, Michael R. Speicher, Ellen Heitzer, Gerald W. Prager	2020	12
10	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis Clinical Cancer Research ·Martin Pichler, Verena Stiegelbauer, Petra Vychytilova‐Faltejskova, Cristina Ivan, Hui Ling, Elke Winter, Xinna Zhang, RAO G.S.P, Annika Wulf-Goldenberg, Masahisa Ohtsuka, Johannes Haybaeck, Marek Svoboda, Yoshinaga Okugawa, Armin Gerger, Gerald Höefler, Ajay Goel, Ondřej Slabý, George A. Călin	2016	61
11	MiR‐96‐5p influences cellular growth and is associated with poor survival in colorectal cancer patients Molecular Carcinogenesis ·Anna Lena Ress, Verena Stiegelbauer, Elke Winter, Daniela Schwarzenbacher, Tobias Kiesslich, Sigurd Lax, 童钢, Alexander Deutsch, Thomas Bauernhofer, Hui Ling, Hellmut Samonigg, Armin Gerger, Gerald Höefler, Martin Pichler	2014	68
12	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing PLoS Genetics ·Sumitra Mohan, Ellen Heitzer, Peter Ulz, Ingrid Lafer, Sigurd Lax, Martina Auer, Martin Pichler, Armin Gerger, Florian Eisner, Gerald Höefler, Thomas Bauernhofer, Jochen B. Geigl, Michael R. Speicher	2014	134
13	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor Journal of Clinical Pathology ·Martin Pichler, Elke Winter, Anna Lena Ress, Thomas Bauernhofer, Armin Gerger, Tobias Kiesslich, Sigurd Lax, Hellmut Samonigg, Gerald Höefler	2013	83
14	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Molecular Cancer Therapeutics ·Yan Ning, Armin Gerger, Wu Zhang, Diana L. Hanna, Dongyun Yang, Thomas Winder, Takeru Wakatsuki, Melissa J. LaBonte, Sebastian Stintzing, Johannes von. Auteur du texte Kittlitz, Yu Sunakawa, Stefan Stremitzer, Rita El‐Khoueiry, Heinz‐Josef Lenz	2013	34
15	A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early‐stage breast cancer Molecular Carcinogenesis ·Gudrun Absenger, Joanna Szkandera, Michael Stotz, Martin Pichler, Thomas Winder, Tanja Langsenlehner, Uwe Langsenlehner, Hellmut Samonigg, Wilfried Renner, Armin Gerger	2013	12
16	The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models Molecular Cancer Therapeutics ·Yan Ning, Melissa J. LaBonte, Wu Zhang, Pierre Bohanes, Armin Gerger, Dongyun Yang, Léonor Benhaïm, David Páez, David O. Rosenberg, Kalyan C. Nagulapalli Venkata, Stan G. Louie, Nicos A. Petasis, Robert D. Ladner, Heinz‐Josef Lenz	2012	102
17	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Clinical Cancer Research ·Armin Gerger, Anthony B. El-Khoueiry, Wu Zhang, Dongyun Yang, Harpreet Singh, Pierre Bohanes, Yan Ning, Thomas Winder, Melissa J. LaBonte, Peter M. Wilson, Léonor Benhaïm, David Páez, Rita El‐Khoueiry, Gudrun Absenger, Heinz‐Josef Lenz	2011	72
18	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients Clinical Cancer Research ·Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	2010	43
19	In vivo confocal scanning laser microscopy of common naevi with globular, homogeneous and reticular pattern in dermoscopy British Journal of Dermatology ·Verena Ahlgrimm‐Siess, Cesare Massone, Sílvia Helena Koller, Regina Fink‐Puches, Erika Richtig, Ingrid Wolf, Armin Gerger, Rainer Hofmann‐Wellenhof	2008	35
20	Automated epiluminescence microscopy—tissue counter analysis using CART and 1‐NN in the diagnosis of Melanoma Skin Research and Technology ·Armin Gerger, (unknown), R. Pompl, Josef Smolle	2003	14

About Armin Gerger

Armin Gerger is a scholar working on Oncology, Cancer Research, Internal Medicine, Pulmonary and Respiratory Medicine and Biophysics, having authored 226 papers that have together received 7.5k indexed citations. Recurring topics across this work include Inflammatory Biomarkers in Disease Prognosis (38 papers), Colorectal Cancer Treatments and Studies (32 papers), Cutaneous Melanoma Detection and Management (31 papers), Cancer Genomics and Diagnostics (24 papers), Genetic factors in colorectal cancer (24 papers), Sarcoma Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer, Lipids, and Metabolism (17 papers). The work is most often cited by research in Oncology (4.7k citations), Cancer Research (1.9k citations), Biophysics (311 citations), Dermatology (447 citations) and Pulmonary and Respiratory Medicine (1.6k citations). Armin Gerger has collaborated with scholars based in Austria, United States and Germany. Frequent co-authors include Martin Pichler, Michael Stotz, Tatjana Stojaković, Joanna Szkandera, Hellmut Samonigg, Josef Smolle, Gudrun Absenger, Uwe Langsenlehner, Sílvia Helena Koller and H. Samonigg. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, The Pharmacogenomics Journal, Annals of Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact